Acceleron Pharma Inc (NASDAQ:XLRN) was upgraded by equities researchers at ValuEngine from a “sell” rating to a “hold” rating in a research report issued on Friday.

Several other brokerages have also issued reports on XLRN. Credit Suisse Group set a $35.00 price target on shares of Acceleron Pharma and gave the company a “buy” rating in a research note on Saturday, August 5th. Oppenheimer Holdings, Inc. reiterated a “market perform” rating on shares of Acceleron Pharma in a research note on Tuesday, June 13th. Piper Jaffray Companies lifted their price target on shares of Acceleron Pharma from $32.00 to $40.00 and gave the company an “overweight” rating in a research note on Monday, June 26th. BidaskClub lowered shares of Acceleron Pharma from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Finally, CIBC lowered shares of Acceleron Pharma from an “outperform” rating to a “market perform” rating in a research note on Tuesday, June 13th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. Acceleron Pharma currently has a consensus rating of “Buy” and a consensus target price of $41.21.

Acceleron Pharma (XLRN) traded down 0.18% during trading on Friday, reaching $38.69. 329,264 shares of the company’s stock traded hands. The firm’s market cap is $1.50 billion. Acceleron Pharma has a 12 month low of $23.07 and a 12 month high of $41.69. The firm has a 50 day moving average price of $33.82 and a 200-day moving average price of $30.07.

Acceleron Pharma (NASDAQ:XLRN) last issued its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by $0.12. Acceleron Pharma had a negative net margin of 970.53% and a negative return on equity of 59.97%. The business had revenue of $3.10 million during the quarter, compared to analyst estimates of $3.69 million. During the same quarter in the previous year, the firm posted ($0.59) earnings per share. The firm’s quarterly revenue was down 3.1% on a year-over-year basis. On average, analysts forecast that Acceleron Pharma will post ($2.73) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was first published by Watch List News and is owned by of Watch List News. If you are accessing this news story on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be accessed at https://www.watchlistnews.com/acceleron-pharma-inc-xlrn-raised-to-hold-at-valuengine/1536918.html.

In related news, SVP Ravindra Kumar sold 13,065 shares of the company’s stock in a transaction dated Tuesday, August 8th. The shares were sold at an average price of $35.41, for a total value of $462,631.65. Following the transaction, the senior vice president now owns 108,392 shares in the company, valued at approximately $3,838,160.72. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO Kevin F. Mclaughlin sold 34,400 shares of the company’s stock in a transaction dated Wednesday, July 5th. The shares were sold at an average price of $32.00, for a total transaction of $1,100,800.00. Following the completion of the transaction, the chief financial officer now owns 80,950 shares in the company, valued at approximately $2,590,400. The disclosure for this sale can be found here. In the last quarter, insiders sold 64,402 shares of company stock worth $2,105,416. 3.90% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in XLRN. Parametric Portfolio Associates LLC raised its position in shares of Acceleron Pharma by 3.9% in the second quarter. Parametric Portfolio Associates LLC now owns 9,456 shares of the biopharmaceutical company’s stock worth $287,000 after buying an additional 355 shares during the period. TD Asset Management Inc. raised its position in shares of Acceleron Pharma by 0.8% in the second quarter. TD Asset Management Inc. now owns 78,800 shares of the biopharmaceutical company’s stock worth $2,395,000 after buying an additional 600 shares during the period. Tudor Investment Corp ET AL raised its position in shares of Acceleron Pharma by 8.5% in the first quarter. Tudor Investment Corp ET AL now owns 9,105 shares of the biopharmaceutical company’s stock worth $241,000 after buying an additional 716 shares during the period. Legal & General Group Plc raised its position in shares of Acceleron Pharma by 9.7% in the second quarter. Legal & General Group Plc now owns 10,470 shares of the biopharmaceutical company’s stock worth $318,000 after buying an additional 923 shares during the period. Finally, Teachers Advisors LLC raised its position in shares of Acceleron Pharma by 2.1% in the first quarter. Teachers Advisors LLC now owns 46,080 shares of the biopharmaceutical company’s stock worth $1,220,000 after buying an additional 942 shares during the period. Institutional investors and hedge funds own 88.07% of the company’s stock.

Acceleron Pharma Company Profile

Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.

Analyst Recommendations for Acceleron Pharma (NASDAQ:XLRN)

Receive News & Ratings for Acceleron Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.